DoD and GSA Take Aim at Supply Chain Risks
Client Alert | 1 min read | 01.15.21
The Department of Defense (DoD) recently implemented additional procedures for the mitigation of cybersecurity risks in its supply chain. Designed to identify and mitigate cybersecurity and related supply chain risks throughout a program’s lifecycle, DoD Instruction 5000.90, Cybersecurity Acquisition Decision Authorities and Program Managers, requires program managers to:
- Assess contractors’ cybersecurity posture, including, where applicable, verifying compliance with the DoD’s newly introduced Cybersecurity Maturity Model Certification (CMMC);
- Consider the extent to which contractors have experienced “significant” incidents resulting in network breaches or data loss;
- Avoid program requirements that may necessitate the use of contractors or suppliers that are owned or controlled by a foreign adversary government or are subject to the jurisdiction of a foreign adversary government;
- Manage any supply chain risks associated with foreign ownership, control, or influence (FOCI); and
- Mitigate supply chain risks using a framework that prescribes escalating risk management actions across four risk tolerance levels.
Alongside the DoD, the General Services Administration (GSA) recently introduced, as part of a draft solicitation for the Polaris small business government-wide IT contract, its own Vendor Risk Assessment Program (VRAP). According to the draft solicitation, the VRAP is designed to identify, assess, and monitor supply chain risks associated with FOCI, cybersecurity, and other factors, such as financial performance.
Contacts
Partner, Crowell Global Advisors Senior Director
- Washington, D.C.
- D | +1.202.624.2698
- Washington, D.C. (CGA)
- D | +1 202.624.2500
Insights
Client Alert | 2 min read | 09.18.25
On September 9, 2025, the U.S. Department of Health and Human Services (HHS) and the Food and Drug Administration (HHS) issued a news release announcing an “aggressive[]” “crackdown” on direct-to-consumer pharmaceutical advertising. This release came on the heels of a Presidential Memorandum President Trump issued the same day directing HHS to “ensure transparency and accuracy in direct-to-consumer prescription drug advertisements,” and the FDA to “take action to enforce legal requirements that advertisements for prescription drugs be truthful and not misleading.”
Client Alert | 3 min read | 09.17.25
Client Alert | 4 min read | 09.17.25
Client Alert | 5 min read | 09.16.25
Bucking the Odds: Why Technology Companies Should Embrace Software Patents Today